Literature DB >> 9364253

Comparison among the effects of arginine, a nitric oxide precursor, isosorbide dinitrate and molsidomine, two nitric oxide donors, on hormonal secretions and blood pressure in man.

M Maccario1, S E Oleandri, M Procopio, S Grottoli, E Avogadri, F Camanni, E Ghigo.   

Abstract

Arginine has well-known stimulatory effects on GH, PRL and insulin secretion in man but the mechanisms underlying these effects are still unclear. More recently, it has been demonstrated that arginine is the precursor of nitric oxide (NO) which mediates its vasodilatatory effect. Thus, it has been hypothesized that NO could also mediate the hormonal effects of arginine. To clarify this point, in seven normal young volunteers (7 normal male subjects, age 26-35 yr) we compared the effects of arginine hydrochloride (ARG, 0.5 g/kg iv over 30 min) on GH, PRL, insulin and glucose levels as well as on blood pressure, with those of isosorbide dinitrate (ISDN, 5 mg po) and molsidomine (MOLS, 4 mg po), two NO donors which possess well-known vasodilatatory effects. ARG infusion elicited a clear-cut GH increase (peak vs baseline 17.6 +/- 4.7 vs 2.7 +/- 0.8 (g/L, p < 0.01), PRL (20.6 +/- 2.8 vs 6.9 +/- 0.5 (g/L, p < 0.01) and insulin levels (31.4 +/- 5.7 vs 4.5 +/- 2.1 (U/L, p < 0.01) while induced a biphasic variation of plasma glucose levels with early increase (p < 0.01), followed by late decrease below basal values (p < 0.01). On the other hand, blood pressure was decreased by ARG (nadir vs baseline; systolic: 103 +/- 6 vs 112 +/- 3, p < 0.02 and diastolic 61 +/- 4 vs 72 +/- 2 mmHg, p < 0.02, respectively). ISDN and MOLS did not modify basal GH, PRL and insulin as well as glucose levels while induced a clear reduction in blood pressure (ISDN: nadir vs baseline; systolic: 94 +/- 4 vs 112 +/- 2, p < 0.02; diastolic 69 +/- 3 vs 80 +/- 2, p < 0.02; MOLS: systolic: 94 +/- 3 vs 113 +/- 2 p < 0.02; diastolic 63 +/- 4 vs 72 +/- 2, p < 0.02). The lowering effect of both ISDN and MOLS on both systolic and diastolic blood pressure levels was higher than that induced by ARG. The effect of the latter was, in turn, significantly different from that of placebo on diastolic levels only. In conclusion, our present date are against the hypothesis that NO mediates the stimulatory effects of arginine on GH, PRL and insulin secretion. On the other hand, our findings agree with the hypothesis that ARG has NO-mediated vasodilatatory effect able to decrease blood pressure in man.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9364253     DOI: 10.1007/BF03348006

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  29 in total

1.  Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme.

Authors:  D S Bredt; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

2.  Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man.

Authors:  P Vallance; J Collier; S Moncada
Journal:  Lancet       Date:  1989-10-28       Impact factor: 79.321

Review 3.  Endothelium-derived relaxing factor. Identification as nitric oxide and role in the control of vascular tone and platelet function.

Authors:  S Moncada; M W Radomski; R M Palmer
Journal:  Biochem Pharmacol       Date:  1988-07-01       Impact factor: 5.858

4.  Prolactin and growth hormone release in response to sequential stimulation by arginine and synthetic TRF.

Authors:  J S Rakoff; T M Siler; Y N Sinha; S S Yen
Journal:  J Clin Endocrinol Metab       Date:  1973-11       Impact factor: 5.958

5.  The nitric oxide synthase II inhibitor NG-nitro-L-arginine stimulates pancreatic islet insulin release in vitro, but not in the perfused pancreas.

Authors:  L Jansson; S Sandler
Journal:  Endocrinology       Date:  1991-06       Impact factor: 4.736

6.  Localization of nitric oxide synthase indicating a neural role for nitric oxide.

Authors:  D S Bredt; P M Hwang; S H Snyder
Journal:  Nature       Date:  1990-10-25       Impact factor: 49.962

7.  Involvement of nitric oxide in growth hormone (GH)-releasing hormone-induced GH secretion in rat pituitary cells.

Authors:  M Kato
Journal:  Endocrinology       Date:  1992-11       Impact factor: 4.736

Review 8.  Clinical comparison of nitrates and sydnonimines.

Authors:  W Rudolph; J Dirschinger
Journal:  Eur Heart J       Date:  1991-11       Impact factor: 29.983

9.  Insulin secretion from pancreatic B cells caused by L-arginine-derived nitrogen oxides.

Authors:  H H Schmidt; T D Warner; K Ishii; H Sheng; F Murad
Journal:  Science       Date:  1992-02-07       Impact factor: 47.728

10.  Inhibition of nitric oxide synthase in the hypothalamus blocks the increase in plasma prolactin induced by intraventricular injection of interleukin-1 alpha in the rat.

Authors:  V Rettori; N Belova; M Gimeno; S M McCann
Journal:  Neuroimmunomodulation       Date:  1994 Mar-Apr       Impact factor: 2.492

View more
  2 in total

1.  Effects of chronic slow release-lanreotide treatment on insulin-like growth factor system and metabolic parameters in acromegalic patients.

Authors:  V Gasco; G Beccuti; F Marotta; N Prencipe; M Maccario; J Janssen; A J van der Lely; E Ghigo; S Grottoli
Journal:  J Endocrinol Invest       Date:  2011-05-31       Impact factor: 4.256

2.  Nitric oxide stimulates growth hormone secretion from human fetal pituitaries and cultured pituitary adenomas.

Authors:  Tami Rubinek; Hadara Rubinfeld; Moshe Hadani; Gad Barkai; Ilan Shimon
Journal:  Endocrine       Date:  2005-11       Impact factor: 3.633

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.